{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:23:00Z","timestamp":1789669380619,"version":"4.0.1"},"reference-count":192,"publisher":"SAGE Publications","issue":"11-12","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:p>Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease (COVID-19) caused by the novel coronavirus SARS-coronavirus 2 (CoV-2). To combat the devastating spread of SARS-CoV-2, extraordinary efforts from numerous laboratories have focused on the development of effective and safe vaccines. Traditional live-attenuated or inactivated viral vaccines are not recommended for immunocompromised patients as the attenuated virus can still cause disease via phenotypic or genotypic reversion. Subunit vaccines require repeated dosing and adjuvant use to be effective, and DNA vaccines exhibit lower immune responses. mRNA vaccines can be highly unstable under physiological conditions. On the contrary, naturally antigenic viral vectors with well-characterized structure and safety profile serve as among the most effective gene carriers to provoke immune response via heterologous gene transfer. Viral vector-based vaccines induce both an effective cellular immune response and a humoral immune response owing to their natural adjuvant properties via transduction of immune cells. Consequently, viral vectored vaccines carrying the SARS-CoV-2 spike protein have recently been generated and successfully used to activate cytotoxic T cells and develop a neutralizing antibody response. Recent progress in SARS-CoV-2 vaccines, with an emphasis on gene therapy viral vector-based vaccine development, is discussed in this review.<\/jats:p>","DOI":"10.1089\/hum.2021.052","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T03:31:33Z","timestamp":1618543893000},"page":"541-562","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination"],"prefix":"10.1177","volume":"32","author":[{"given":"Atil","family":"Bisgin","sequence":"first","affiliation":[{"name":"The Department of Gene and Cell Therapy, Faculty of Medicine, Akdeniz University, Antalya, Turkey."},{"name":"Department of Medical Genetics, Faculty of Medicine, Cukurova University, Adana, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahter D.","family":"Sanlioglu","sequence":"additional","affiliation":[{"name":"The Department of Gene and Cell Therapy, Faculty of Medicine, Akdeniz University, Antalya, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunus Emre","family":"Eksi","sequence":"additional","affiliation":[{"name":"The Department of Gene and Cell Therapy, Faculty of Medicine, Akdeniz University, Antalya, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Griffith","sequence":"additional","affiliation":[{"name":"The Department of Urology, School of Medicine, University of Minnesota, Minneapolis, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8379-5678","authenticated-orcid":false,"given":"Salih","family":"Sanlioglu","sequence":"additional","affiliation":[{"name":"The Department of Gene and Cell Therapy, Faculty of Medicine, Akdeniz University, Antalya, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,6,16]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.01.009"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2012-7"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2607.200282"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0994"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2020.06.017"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02132"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00352-y"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.07.021"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","unstructured":"Tang X Wu C Li X et al. On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev 2020 [Epub ahead of print]; DOI: 10.1093\/nsr\/nwaa036.","DOI":"10.1093\/nsr\/nwaa036"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2895-3"},{"key":"e_1_3_5_14_2","doi-asserted-by":"crossref","unstructured":"Shi PY Plante J Liu Y et al. Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility. Res Sq 2020;rs.3.rs-70482.","DOI":"10.21203\/rs.3.rs-70482\/v1"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.06.043"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7003e2"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7008e2"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2021.198345"},{"key":"e_1_3_5_19_2","doi-asserted-by":"crossref","unstructured":"Hoffmann M Arora P Gross R et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 2021 [Epub ahead of print]; DOI: 10.1016\/j.cell.2021.03.036.","DOI":"10.1016\/j.cell.2021.03.036"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8020153"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40779-020-00240-0"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2020.104211"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000513198"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01949"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S258639"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05190-5"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/med.21756"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.20506\/rst.21.3.1361"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2015.03.032"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1506702"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2090"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.06.084"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.05.023"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.09.106"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2180-5"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-virology-110615-042301"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature02463"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.04.016"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0401939101"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.5.2678-2688.2005"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac7462"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.08.011"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12250-018-0009-2"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.6b00006"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.123158"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1107.050219"},{"issue":"2","key":"e_1_3_5_48_2","first-page":"S142","article-title":"Receptor-binding domain as a target for developing SARS vaccines","volume":"5","author":"Zhu X","year":"2013","unstructured":"Zhu X, , Liu Q, , Du L, et al. Receptor-binding domain as a target for developing SARS vaccines. J Thorac Dis, 2013; 5(Suppl 2):S142\u2013S148.","journal-title":"J Thorac Dis"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.08.031"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.02.065"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.01.025"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.2.948"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.11.007"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.05.079"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro1769"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a117611"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1006\/biol.1993.1089"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2007.117952"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.08.048"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.602256"},{"key":"e_1_3_5_61_2","unstructured":"Balfour H. First patient dosed with COVI-VAC an intranasal COVID-19 vaccine candidate. European Pharmaceutical Review. https:\/\/www.europeanpharmaceuticalreview.com\/news\/139089\/first-patient-dosed-with-covi-vac-an-intranasal-covid-19-vaccine-candidate\/ (last accessed January12 2021)."},{"key":"e_1_3_5_62_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.7.10.16369"},{"key":"e_1_3_5_63_2","doi-asserted-by":"crossref","unstructured":"Zhang Y Zeng G Pan H et al. Safety tolerability and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomised double-blind placebo-controlled phase 1\/2 clinical trial. Lancet Infect Dis 2020 [Epub ahead of print]; DOI: 10.1016\/S1473-3099(20)30987-7.","DOI":"10.1016\/S1473-3099(20)30843-4"},{"key":"e_1_3_5_64_2","unstructured":"Reuters Staff. China's Sinovac vaccine has \u201cgeneral efficacy\u201d of 50.4% in Brazil trials says Butantan. Reuters Biotechnology. https:\/\/www.reuters.com\/article\/healthcoronavirus-brazil-coronavirus-idUSE5N2HA01G (last accessed January12 2021)."},{"key":"e_1_3_5_65_2","doi-asserted-by":"crossref","unstructured":"Srivastava RK Ish P Safdarjung Covid-Vaccination Group. The initial experience of COVID-19 vaccination from a tertiary care centre of India. Monaldi Arch Chest Dis 2021 [Epub ahead of print]; DOI: 10.4081\/monaldi.2021.1816.","DOI":"10.4081\/monaldi.2021.1816"},{"key":"e_1_3_5_66_2","doi-asserted-by":"crossref","unstructured":"Ella R Vadrevu KM Jogdand H et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine BBV152: a double-blind randomised phase 1 trial. Lancet Infect Dis 2021 [Epub ahead of print]; DOI: 10.1101\/2020.12.21.20248643.","DOI":"10.1016\/S1473-3099(20)30942-7"},{"key":"e_1_3_5_67_2","unstructured":"Ella R Reddy S Jogdand H et al. Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine BBV152 (a phase 2 double-blind randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report. medRxiv 2020 [Epub ahead of print]; 10.1101\/2020.12.21.20248643."},{"key":"e_1_3_5_68_2","unstructured":"Kumar RN. Coronavirus | Covaxin efficacy is 81% works against variants. The Hindu. https:\/\/www.thehindu.com\/sci-tech\/health\/bharat-biotech-says-covid-19-vaccine-shows-81-interim-efficacy\/article33980224.ece (last accessed March3 2021)."},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.200"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.12.032"},{"key":"e_1_3_5_71_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243"},{"key":"e_1_3_5_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.12.003"},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.16866"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027906"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"e_1_3_5_76_2","unstructured":"Lewis T . Pfizer-BioNTech COVID vaccine is first to win U.S . authorization. Scientific American. https:\/\/www.scientificamerican.com\/article\/pfizer-biontech-covid-vaccine-is-first-to-win-u-s-authorization\/ (last accessed December11 2020)."},{"key":"e_1_3_5_77_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022483"},{"key":"e_1_3_5_78_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"e_1_3_5_79_2","doi-asserted-by":"crossref","unstructured":"Dolgin E. COVID-19 vaccines poised for launch but impact on pandemic unclear. Nat Biotechnol 2020 [Epub ahead of print]; DOI: 10.1038\/d41587-020-00022-y.","DOI":"10.1038\/d41587-020-00022-y"},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics6030378"},{"key":"e_1_3_5_81_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7020037"},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118919"},{"key":"e_1_3_5_83_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09518-1"},{"key":"e_1_3_5_84_2","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201102834"},{"key":"e_1_3_5_85_2","unstructured":"Davey M . Australia terminates University of Queensland vaccine deal with CSL after false positives for HIV . The Guardian. https:\/\/www.theguardian.com\/world\/2020\/dec\/11\/australia-terminates-university-of-queensland-vaccine-deal-with-csl-after-false-positives-for-hiv (last accessed December11 2020)."},{"key":"e_1_3_5_86_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.27332"},{"key":"e_1_3_5_87_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.578382"},{"key":"e_1_3_5_88_2","doi-asserted-by":"publisher","DOI":"10.3390\/genes10030189"},{"key":"e_1_3_5_89_2","doi-asserted-by":"publisher","DOI":"10.3390\/v12111324"},{"key":"e_1_3_5_90_2","doi-asserted-by":"publisher","DOI":"10.4155\/tde.10.84"},{"key":"e_1_3_5_91_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.11.9485-9495.1999"},{"key":"e_1_3_5_92_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.46088-0"},{"key":"e_1_3_5_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.11.028"},{"key":"e_1_3_5_94_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00487-6"},{"key":"e_1_3_5_95_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0696-714"},{"key":"e_1_3_5_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2017.04.001"},{"key":"e_1_3_5_97_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.11.6539"},{"key":"e_1_3_5_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2003.11.017"},{"key":"e_1_3_5_99_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-5-54"},{"key":"e_1_3_5_100_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7701087"},{"key":"e_1_3_5_101_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700877"},{"key":"e_1_3_5_102_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700394"},{"key":"e_1_3_5_103_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.5.2886"},{"key":"e_1_3_5_104_2","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2001.0439"},{"key":"e_1_3_5_105_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1526"},{"key":"e_1_3_5_106_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031085"},{"key":"e_1_3_5_107_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.286.5443.1381"},{"key":"e_1_3_5_108_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00909"},{"key":"e_1_3_5_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.04.026"},{"key":"e_1_3_5_110_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.10.002"},{"key":"e_1_3_5_111_2","doi-asserted-by":"crossref","unstructured":"King RG Silva-Sanchez A Peel JN et al. Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 in mice. bioRxiv 2020 [Epub ahead of print]; DOI: 10.1101\/2020.10.10.331348.","DOI":"10.1101\/2020.10.10.331348"},{"key":"e_1_3_5_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31208-3"},{"key":"e_1_3_5_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31605-6"},{"key":"e_1_3_5_114_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00937"},{"key":"e_1_3_5_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31604-4"},{"key":"e_1_3_5_116_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32661-1"},{"key":"e_1_3_5_117_2","doi-asserted-by":"crossref","unstructured":"Phillips N Cyranoski D Mallapaty S. A leading coronavirus vaccine trial is on hold: scientists react. Nature 2020 [Epub ahead of print]; DOI: 0.1038\/d41586-020-02594-w.","DOI":"10.1038\/d41586-020-02594-w"},{"key":"e_1_3_5_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2020.10.023"},{"key":"e_1_3_5_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00234-8"},{"key":"e_1_3_5_120_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.180"},{"key":"e_1_3_5_121_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-018-0011-1"},{"key":"e_1_3_5_122_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-bioeng-071813-104938"},{"key":"e_1_3_5_123_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2016.17"},{"key":"e_1_3_5_124_2","doi-asserted-by":"publisher","DOI":"10.1089\/hgtb.2013.015"},{"key":"e_1_3_5_125_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0106-0"},{"key":"e_1_3_5_126_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.11.8463-8471.1998"},{"key":"e_1_3_5_127_2","doi-asserted-by":"publisher","DOI":"10.1007\/7651_2018_154"},{"key":"e_1_3_5_128_2","doi-asserted-by":"publisher","DOI":"10.1007\/7651_2018_150"},{"key":"e_1_3_5_129_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.10.8150-8157.1998"},{"key":"e_1_3_5_130_2","doi-asserted-by":"crossref","unstructured":"Erendor F Sahin EO Sanlioglu AD et al. Lentiviral gene therapy vectors encoding VIP suppressed diabetes-related inflammation and augmented pancreatic beta-cell proliferation. Gene Ther 2020 [Epub ahead of print]; DOI: 10.1038\/s41434-020-0183-3.","DOI":"10.1038\/s41434-020-0183-3"},{"key":"e_1_3_5_131_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.10.025"},{"key":"e_1_3_5_132_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.122"},{"key":"e_1_3_5_133_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2005.16.149"},{"key":"e_1_3_5_134_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200317098"},{"key":"e_1_3_5_135_2","doi-asserted-by":"publisher","DOI":"10.1089\/104303402753812494"},{"key":"e_1_3_5_136_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.4.1327"},{"key":"e_1_3_5_137_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.1.114"},{"key":"e_1_3_5_138_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302697"},{"key":"e_1_3_5_139_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.03.014"},{"key":"e_1_3_5_140_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2597"},{"key":"e_1_3_5_141_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21072657"},{"key":"e_1_3_5_142_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.12.010"},{"key":"e_1_3_5_143_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.19.9184-9196.2000"},{"key":"e_1_3_5_144_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3300967"},{"key":"e_1_3_5_145_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw2900"},{"key":"e_1_3_5_146_2","doi-asserted-by":"publisher","DOI":"10.1089\/10430349950018661"},{"key":"e_1_3_5_147_2","doi-asserted-by":"publisher","DOI":"10.3390\/v13010101"},{"key":"e_1_3_5_148_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddz148"},{"key":"e_1_3_5_149_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11262-017-1502-7"},{"key":"e_1_3_5_150_2","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2016.66"},{"key":"e_1_3_5_151_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00008-08"},{"key":"e_1_3_5_152_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01675-12"},{"key":"e_1_3_5_153_2","doi-asserted-by":"publisher","DOI":"10.2174\/1566523013348788"},{"key":"e_1_3_5_154_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.171"},{"key":"e_1_3_5_155_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.12.6716"},{"key":"e_1_3_5_156_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2006.03.049"},{"key":"e_1_3_5_157_2","doi-asserted-by":"crossref","unstructured":"Zabaleta N Dai W Bhatt U et al. Immunogenicity of an AAV-based room-temperature stable single dose COVID-19 vaccine in mice and non-human primates. bioRxiv 2021 [Epub ahead of print]; DOI: 10.1101\/2021.01.05.422952.","DOI":"10.1101\/2021.01.05.422952"},{"key":"e_1_3_5_158_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsb.2014.03.020"},{"key":"e_1_3_5_159_2","unstructured":"The U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibodies for treatment of COVID-19. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19 (last accessed November21 2020)."},{"key":"e_1_3_5_160_2","unstructured":"Moody M. Penn medicine collaborates with regeneron to investigate delivery of COVID-19 antibody cocktail via gene therapy platform. Penn Medicine. https:\/\/www.pennmedicine.org\/news\/news-releases\/2020\/november\/penn-medicine-collaborates-with-regeneron-to-investigate-delivery-of-covid-antibody (last accessed November30 2020)."},{"key":"e_1_3_5_161_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.01.001"},{"key":"e_1_3_5_162_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2003.08.016"},{"key":"e_1_3_5_163_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00005"},{"key":"e_1_3_5_164_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005795"},{"key":"e_1_3_5_165_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.244"},{"key":"e_1_3_5_166_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aal1329"},{"key":"e_1_3_5_167_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00171"},{"key":"e_1_3_5_168_2","doi-asserted-by":"publisher","DOI":"10.3390\/v13020217"},{"key":"e_1_3_5_169_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2018.01.005"},{"key":"e_1_3_5_170_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2014468117"},{"key":"e_1_3_5_171_2","doi-asserted-by":"crossref","unstructured":"Frantz PN Barinov A Ruffi\u00e9 C et al. A measles-vectored COVID-19 vaccine induces long-term immunity and protection from SARS-CoV-2 challenge in mice. bioRxiv 2021 [Epub ahead of print]; DOI: 10.1101\/2021.02.17.43163","DOI":"10.1101\/2021.02.17.431630"},{"key":"e_1_3_5_172_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19819-1"},{"key":"e_1_3_5_173_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.07.018"},{"key":"e_1_3_5_174_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20228-7"},{"key":"e_1_3_5_175_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.04.073"},{"key":"e_1_3_5_176_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.10.087"},{"key":"e_1_3_5_177_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.318.5853.1048"},{"key":"e_1_3_5_178_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20072681"},{"key":"e_1_3_5_179_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-00789-5"},{"key":"e_1_3_5_180_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00434-6"},{"key":"e_1_3_5_181_2","doi-asserted-by":"crossref","unstructured":"Cobey S Larremore DB Grad YH et al. Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination. Nat Rev Immunol 2021 [Epub ahead of print]; DOI: 10.1038\/s41577-021-00544-9.","DOI":"10.1038\/s41577-021-00544-9"},{"key":"e_1_3_5_182_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32623-4"},{"key":"e_1_3_5_183_2","unstructured":"Medicines and Healthcare Products Regulatory Agency. Information for healthcare professionals on covid-19 vaccine AstraZeneca. https:\/\/www.gov.uk\/government\/publications\/regulatory-approval-of-covid-19-vaccine-astrazeneca\/information-for-healthcare-professionals-on-covid-19-vaccine-astrazeneca (last accessed January5 2020)."},{"key":"e_1_3_5_184_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n18"},{"key":"e_1_3_5_185_2","unstructured":"UK Joint Committee on Vaccination and Immunisation. Advice on priority groups for COVID-19 vaccination. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/950113\/jcvi-advice-on-priority-groups-for-covid-19-vaccination-30-dec-2020-revised.pdf (last accessed December30 2020)."},{"key":"e_1_3_5_186_2","unstructured":"Joint Committee on Vaccination and Immunisation (UK). Optimising the COVID-19 vaccination programme for maximum short-term impact. Short statement from the Joint Committee on Vaccination and Immunisation (JCVI). https:\/\/www.app.box.com\/s\/uwwn2dv4o2d0ena726gf4403f3p2acnu (last accessed December31 2020)."},{"key":"e_1_3_5_187_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00432-3"},{"key":"e_1_3_5_188_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmni.2020.100672"},{"key":"e_1_3_5_189_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.02.001"},{"key":"e_1_3_5_190_2","doi-asserted-by":"publisher","DOI":"10.1002\/bit.26461"},{"key":"e_1_3_5_191_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.01.001"},{"key":"e_1_3_5_192_2","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-10-74"},{"key":"e_1_3_5_193_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.11.9468-9477.1999"}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/hum.2021.052","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2021.052","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2021.052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:55:39Z","timestamp":1777449339000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hum.2021.052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":192,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1089\/hum.2021.052"],"URL":"https:\/\/doi.org\/10.1089\/hum.2021.052","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}